ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial
Information source: UMC Utrecht
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Brain Ischemia; Transient Ischemic Attack; Arteriosclerosis
Intervention: anticoagulation (Drug); aspirin and dipyridamole (Drug); aspirin alone (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: UMC Utrecht Official(s) and/or principal investigator(s): A. Algra, Professor, Principal Investigator, Affiliation: UMC Utrecht J. Gijn Van, Professor, Principal Investigator, Affiliation: UMC Utrecht
Summary
The objective of ESPRIT was to compare the efficacy and safety of mild anticoagulation or a
combination treatment of aspirin and dipyridamole with the efficacy and safety of treatment
with aspirin alone after cerebral ischemia of arterial origin.
Clinical Details
Official title: ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: The combined event of death from all vascular causes, nonfatal stroke, nonfatal myocardial infarction or major bleeding complication, whichever happens first during follow-up
Secondary outcome: Death from all causesdeath from vascular causes death from vascular causes or nonfatal stroke fatal or nonfatal stroke death from vascular causes, nonfatal stroke, nonfatal myocardial infarction or vascular intervention major bleeding complications amputations of lower extremities retinal infarction or bleeding
Detailed description:
Low-dose aspirin (ASA) (at least 30 mg/day) prevents only 13% of subsequent vascular events
after minor cerebral ischemia of arterial origin. Anticoagulation (AC) has been proven
highly effective in preventing vascular events after myocardial infarction and after
cerebral ischemia in patients with atrial fibrillation. A previous study on the effects of
AC after cerebral ischemia of arterial origin (SPIRIT) showed that high intensity AC (INR
3. 0 to 4. 5) is not safe, but that mild AC (INR 2. 0 to 3. 0) was. The 2nd European Stroke
Prevention Trial (ESPS-2) reported a 22% relative risk reduction of the combination of ASA
and dipyridamole (DIP) above that of ASA only; its results, however, are subject to debate.
Study design: ESPRIT was an open randomised controlled trial allocating patients who
experienced a transient ischemic attack (TIA) or a non-disabling ischemic stroke to either:
A. oral AC (INR 2. 0 to 3. 0);
B. the combination of DIP (400 mg daily) plus ASA (30-325 mg/day); or
C. ASA only (same dose).
The mean follow-up was three years. Primary outcome was the composite of vascular death,
stroke, myocardial infarction or major bleeding. Outcome assessment is blind.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients presenting in the participating hospitals with a TIA or non-disabling stroke
of atherosclerotic origin
- Randomisation within 6 months after the TIA or minor stroke
- Modified Rankin scale of 3 or less
Exclusion Criteria:
- (Contra)indication to, or intolerance to, anticoagulants, dipyridamole, or aspirin
- Disease expected to cause death within weeks or months
- Source of embolism in the heart
- Moderate or severe ischemic damage to the white matter of the brain (leukoaraiosis)
- Anemia, polycythemia, thrombocytosis, or thrombocytopenia
- Planned carotid endarterectomy
- Intracranial bleeding or cerebral tumour
- TIA or stroke caused by vasculitis, migraine, or dissection
- Severe hypertension
- Liver failure
- Pregnancy
- Chronic alcohol abuse
Locations and Contacts
UMC Utrecht, Utrecht, Netherlands
Additional Information
Starting date: July 1997
Last updated: March 21, 2007
|